Serial No.: 10/057,467 **Filed:** January 22, 2002

.님.

REMARKS

New claims 8-25 are pending. Claims 1-7 have been canceled. Support for the new claims is found throughout the specification and as further described. New claim 8 is identical to claim 1 of U.S. Patent No. 6,153,380, (a continuation-in-part of the present application), with the addition of "wherein each of said retroviral vectors comprises a nucleic acid encoding at least one glycine N-terminal to the randomized peptide," and "identifying said transdominant bioactive agent." The claim is supported at p. 3, lines 6-11, p. 7, lines 23-24, and p. 9, lines 2-4.

Support for new claim 9 is at p. 3, line 11; for new claim 10, at p. 9, lines 21-22; for new claim 11, at p. 5, lines 6-8; for new claim 12, at p. 7, lines 18-20; for new claims 13-18, at p. 4, lines 6-7; for new claim 19, at p. 4, line 25; and for new claim 20, p. 14, lines 2-3.

New claims 21-23 are identical to claim 1 of U.S. Patent No. 6,153,380, (a continuation-in-part of the present application), but further specify that the altered phenotype is cell growth (claim 21), cell death (claim 22) or a change in expression of cellular differentiation markers (claim 23). Furthermore, the limitation "identifying said transdominant bioactive agent" is included in each claim. Claims 21-22 have support at p. 7, lines 4-5; claims 23-25 have support at p. 7, lines 3-5.

Applicants respectfully submit that the claims are in condition for allowance, and an early notification of such is respectfully requested. Please direct any calls in connection with this application to the undersigned attorney.

Serial No.: 10/057,467 **Filed:** January 22, 2002

Respectfully submitted,

FLEHR HOHBACH TEST ALBRITTON & HERBERT LLP

Anne M. Shyjan, Reg. No. 47,086, for Robin M. Silva, Reg. No. 38,304

Dated: February 13, 2002
Four Embarcadero Center, Suite 3400

San Francisco, CA 94111-4187 Telephone: (415) 781-1989

1074359